Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult
MTX‑IR patients1

Defy expectations Defy expectations Defy expectations

RINVOQ met ALL primary (ACR20, ACR50, or ΔDAS28-CRP at Week 12 or 14) and ranked secondary endpoints across clinical trials.1-4  See results below

*Formulary definitions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non‑preferred products require a higher out‑of‑pocket cost or step edit, or are placed on a higher tier. Coverage means placed on formulary without a step edit through other biologics. For RINVOQ, this could include coverage on a non‑preferred tier, which may result in a higher out-of-pocket cost.
Based on formulary status under the pharmacy benefit.
National commercial coverage as of April 2020.
Data on File, AbbVie Inc. Payer-reported lives. April 2020.

ACR=American College of Rheumatology; DAS28=disease activity score 28 joints; IR=intolerance or inadequate response; MTX=methotrexate

discover superiority data in separate head-to-head trials vs. 2 biologics discover superiority data in separate head-to-head trials vs. 2 biologics discover superiority data in separate head-to-head trials vs. 2 biologics

In clinical trials, RINVOQ met all primary and ranked
secondary endpoints2

Primary Endpoint Results
(Week 12 or 14)

28
52*
41
68*
36
64*
28
65*
36
71*
-2.00
-2.52
Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14)

SELECT‑EARLY
(Study RA‑I):1,5

48‑week, randomized, double‑blind, active comparator‑controlled study of 947 adult patients with moderate to severe RA who were MTX‑naïve.

SELECT‑MONOTHERAPY
(Study RA‑II):1,6

14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX.

SELECT‑NEXT
(STUDY RA‑III)1,7

12‑week, randomized, double‑blind, placebo‑controlled study of 661 adult patients with moderate to severe RA who had an inadequate response to csDMARDs.

SELECT‑BEYOND
(Study RA‑V):1,8

12‑week, randomized, double‑blind, placebo‑controlled study of 499 adult patients with moderate to severe RA who have had an inadequate response or intolerance to bDMARDs.

SELECT‑COMPARE
(Study RA‑IV):1,9

48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX.

SELECT‑CHOICE3
24‑week, randomized, double‑blind, active comparator‑controlled, study of 612 adult patients with moderate to severe RA who have had an inadequate response or intolerance to bMARDs.

RINVOQ is a once-daily JAK inhibitor1

Separate Head‑To‑Head Trial Results vs 2 Biologics3,9

RINVOQ + csDMARDs demonstrated superiority in ranked secondary endpoints at Week 12:

‑ vs HUMIRA + MTX (ACR50, HAQ‑DI, pain reduction) in SELECT‑COMPARE

‑ vs ORENCIA® (abatacept) + csDMARDs (DAS28‑CRP<2.6) in SELECT‑CHOICE

Durable remission, even without MTX1,10,12

DAS28-CRP<2.6* at Week 12 or 14, with response rates up to 84 weeks

*Does not mean drug-free remission or complete absence of disease activity

Radiographic inhibition, even without MTX1,13

∆mTSS at Week 24 or 26 with responses observed up to 96 weeks

RINVOQ is not indicated for
MTX-naïve patients

Safety data from 5 robust Phase 3 trials1,‡

>4350 patients across treatment arms,14,§ >4500 patient‑years, ~3.5 years maximum and 2 years median long‑term exposure to RINVOQ 15 mg as of 6/30/1911

Commitment to exceptional access and patient support

>95% preferred national commercial coverage15,ǁ,¶ and 1:1 support to help patients start and stay on track with their prescribed treatment plan

SELECT‑MONOTHERAPY, SELECT‑EARLY, SELECT‑NEXT, SELECT-COMPARE and SELECT‑BEYOND
§RINVOQ 15 mg; upadacitinib 30 mg; methotrexate; HUMIRA (adalimumab); placebo
ǁFormulary defintions: Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. Coverage means placed on formulary without a step edit through other biologics. For RINVOQ, this could include coverage on a non-preferred tier, which may result in a higher out‑of‑pocket cost.
Based on formulary status under the pharmacy benefit.

ACR=American College of Rheumatology; CRP=C-reactive protein; csDMARDs=conventional synthetic disease-modifying antirheumatic drugs; DAS28=disease activity score 28 joints; HAQ‑DI=health assessment questionnaire disability index; JAK=Janus kinase; mTSS=modified total Sharp score; MTX=methotrexate

RINVOQ™ COMPLETE

See how UPADAC Complete provides an exceptional access
and patient support experience

QUESTIONS ABOUT COVID-19?
CLICK HERE.

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking